

Revised forms for the submission of the Confidence-Building Measures

At the Third Review Conference it was agreed that all States Parties present the following declaration, later amended by the Seventh Review Conference:

Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part 1	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
B	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
C	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
F	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
G	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

(Please mark the appropriate box(es) for each measure with a tick, and fill in the year of last declaration in the last column where applicable.)

Date: **15 April 2015**

State Party to the Convention: **JAPAN**

Date of ratification/accession to the Convention: **8 June 1982**

National point of contact: **Eva NAKAMURA, Ministry of Foreign Affairs of Japan**

Confidence-Building Measure "A"

Part 1 Exchange of data on research centres and laboratories

Form A, part 1 (i)

Exchange of data on research centres and laboratories

(1)

1. Name(s) of facility : **RIKEN Tsukuba Campus**
2. Responsible public or private organization or company:
The Institute of Physical and Chemical Research (RIKEN)
3. Location and postal address: **3-1-1, Koyadai, Tsukuba-shi, Ibaraki, 305-0074, JAPAN**
4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence:
Ministry of Education, Culture, Sports, Science and Technology
5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m²):
2 units, 82 m²
6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate:
Risk assessment of recombinant DNA materials using Retrovirus

(2)

1. Name(s) of facility:

Murayama Annex of National Institute of Infectious Diseases (former National Institute of Health)

2. Responsible public or private organization or company:

Ministry of Health, Labour and Welfare

3. Location and postal address: **Gakuen4-7-1, Musashimurayama, Tokyo, 208-0011, Japan**

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence:

Ministry of Health, Labour and Welfare

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m²)

Three P4 Laboratories, Seventeen P3 Laboratories and their supporting Laboratories (2,270.36 m² in totals)

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Laboratory diagnosis of viral haemorrhagic fever such as Lassa, Marburg and Ebola diseases (However, such diagnosis has never been performed in these laboratories so far).

Part 2 Exchange of information on national biological defence research and development programmes

Form A, part 2 (i)

National biological defence research and development programmes Declaration

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes / ~~No~~

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

Form A, part 2 (ii)

National biological defence research and development programmes

Description

1. State the objectives and funding of each programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

The Japan Ground Self-Defense Force's biological defence research and development programmes for FY2015 includes: Research of molecular biological diagnosis for biological agent casualties

2. State the total funding for each programme and its source.

Approximately 1,804,000 Japanese yen, founded by the Ministry of Defense

3. Are aspects of these programmes conducted under contract with industry, academic institutions, or in other non-defence facilities?

~~Yes~~ / No

4. If yes, what proportion of the total funds for each programme is expended in these contracted or other facilities?
5. Summarize the objectives and research areas of each programme performed by contractors and in other facilities with the funds identified under paragraph 4.
6. Provide a diagram of the organizational structure of each programme and the reporting relationships (include individual facilities participating in the programme).
7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to each national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

Form A, part 2 (iii)

National biological defence research and development programmes

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?

Military Medicine Research Unit, Test & Evaluation Command, Japan Ground Self-Defense Force

2. Where is it located (include both address and geographical location)?

1-2-24, Ikejiri Setagaya-ku, Tokyo 154-0001, Japan

3. Floor area of laboratory areas by containment level:

BL2 Approximately 42 (sqM)

BL3 0 (sqM)

BL4 0 (sqM)

Total laboratory floor area 104 (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel _____

(ii) Division of personnel:

Military _____

Civilian _____

(iii) Division of personnel by category:

Scientists _____

Engineers _____

Technicians _____

Administrative and support staff _____

(iv) List the scientific disciplines represented in the scientific/engineering staff.

Ph.D.of Medicine

(v) Are contractor staff working in the facility? If so, provide an approximate number.

No

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

The Ministry of Defense (wholly)

(vii) What are the funding levels for the following programme areas:

Research **cannot be divided into each area**

Development **cannot be divided into each area**

Test and evaluation **cannot be divided into each area**

(viii) Briefly describe the publication policy of the facility:

No official policy. Individually authorized by the MOD.

(ix) Provide a list of publicly-available papers and reports resulting from the work published during the previous 12 months. (To include authors, titles and full references.)

None

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms and/or toxins studied, as well as outdoor studies of biological aerosols.

Research and Development of medical diagnosis/treatment and prevent medicine for casualties in action.

Confidence-Building Measure "C"

Encouragement of publication of results and promotion of use of knowledge

The Government of Japan maintains an open policy on the exchange of information on biological research, the results of such research being made freely available in all cases where the release is not prejudicial to vital national or commercial interests. This policy would be apply to any research subject to the reporting in Forms A and B.

Relevant information of National Institute of Infectious Disease (NIID) is available at the following site.

1) Lists of scientific papers in English and Japanese, which are published by the staffs of National Institute of Infectious Disease (NIID), can be seen in the web site of NIID.

<http://www.nih.go.jp/niid/en/>

2) NIID publishes bimonthly Japanese Journal of Infectious Diseases (JJID), the leading infectious disease journal in Japan. JJID receives more than 250 manuscripts per year from authors around the world. It has been donated to more than 75 countries. JJID is available at the journal site.

<http://www.nih.go.jp/niid/en/>

Selected articles published in the journal :

Hotta A, Tanabayashi K, Fujita O, Shindo J, Park CH, Kudo N, Hatai H, Oyamada T, Yamamoto Y, Takano A, Kawabata H, Sharma N, Uda A, Yamada A, Morikawa S. Survey of Francisella tularensis in Wild Animals in the Endemic Areas in Japan. Jpn J Infect Dis. 2015 Nov 13. [Epub ahead of print]

Shirato K, Azumano A, Nakao T, Hagihara D, Ishida M, Tamai K, Yamazaki K, Kawase M, Okamoto Y, Kawakami S, Okada N, Fukushima K, Nakajima K, Matsuyama S. Middle East respiratory syndrome coronavirus infection not found in camels in Japan. Jpn J Infect Dis. 2015;68(3):256-8.

Takayama I, Takahashi H, Nakauchi M, Nagata S, Tashiro M, Kageyama T. Development of a diagnostic system for novel influenza A(H7N9) virus using a real-time RT-PCR assay in Japan. Jpn J Infect Dis. 2015;68(2):113-8.

Fujimoto T, Yamane S, Ogawa T, Hanaoka N, Ogura A, Hotta C, Niwa T, Chiba Y, Gonzalez G, Aoki K, Ono K, Koyanagi, Watanabe H: A Novel Complex Recombinant Form of Type 48-Related Human Adenovirus Species D Isolated in Japan. Jap J Infect Dis 67(4) 284-287, 2014

Shimojima M, Fukushi S, Tani H, Yoshikawa T, Fukuma A, Taniguchi S, Suda Y, Maeda K, Takahashi T, Morikawa S, Saijo M. Effects of ribavirin on severe fever with thrombocytopenia syndrome virus in vitro. Jpn J Infect Dis. 67(6):423-427, 2014

Hotta A, Fujita O, Uda A, Sharma N, Tanabayashi K, Yamamoto Y, Yamada A, Morikawa S. In vitro antibiotic susceptibility of Francisella tularensis isolates from Japan. Jpn J Infect Dis. 2013;66(6):534-6.

Fujita O, Hotta A, Uda A, Yamamoto Y, Fujita H, Shinya F, Asano S, Morikawa S, Tanabayashi K, Yamada A. Identification of the source of Francisella tularensis infection by multiple-locus variable-number tandem repeat analysis. Jpn J Infect Dis. 2013;66(6):543-5.

Kishida N, Imai M, Xu H, Taya K, Fujisaki S, Takashita E, Tashiro M, Odagiri T.:Seroprevalence of a novel influenza A (H3N2) variant virus in the Japanese population.Jpn J Infect Dis. 2013;66(6):549-51.

Kameyama M, Yabata J, Nomura Y, Tominaga K.:Investigation of a diffused outbreak in Yamaguchi Prefecture in 2012 using multiple molecular typing methods. Jpn J Infect Dis. 2013;66(4):355-7.

Obuchi M, Toda S, Tsukagoshi H, Oogane T, Abiko C, Funatogawa K, Mizuta K, Shirabe K, Kozawa K, Noda M, Kimura H, Tashiro M.:Molecular analysis of genome of the pandemic influenza A(H1N1) 2009 virus associated with fatal infections in Gunma, Tochigi, Yamagata, and Yamaguchi prefectures in Japan during the first pandemic wave.Jpn J Infect Dis. 2012 Jul;65(4):363-7

3) Publications in other journals

- Hotta A, Fujita O, Uda A, Yamamoto Y, Sharma N, Tanabayashi K, Yamada A, Morikawa S. Virulence of Representative Japanese *Francisella tularensis* and Immunologic Consequence of Infection in Mice. *Microbiol Immunol*. 2016 Feb 8. [Epub ahead of print]
- Buddhisa S, Rinchai D, Ato M, Bancroft G, Lertmemongkolchai G. Programmed Death-Ligand 1 on *Burkholderia pseudomallei* infected human polymorphonuclear neutrophils impairs T cell functions. *J Immunol*. 2015 194(9):4413-21.
- Rinchai D, Riyapa D, Buddhisa S, Utispan K, Titball RW, Stevens MP, Stevens JM, Ogawa M, Tanida I, Koike M, Uchiyama Y, Ato M*, Lertmemongkolchai G*. Macroautophagy is essential for killing of intracellular *Burkholderia pseudomallei* in human neutrophils. *Autophagy*. 2015 11(5) 748-755.
- Bukbuk DN, Fukushi S, Tani H, Yoshikawa T, Taniguchi S, Iha K, Fukuma A, Shimojima M, Morikawa S, Saijo M, Kasolo F, Baba SS. Development and validation of serological assays for viral hemorrhagic fevers and determination of the prevalence of Rift Valley fever in Borno State, Nigeria. *Trans R Soc Trop Med Hyg*. 2014 108(12):768-73.
- Kobayashi T, Hayakawa K, Mawatari M, Mezaki K, Takeshita N, Kutsuna S, Fujiya Y, Kanagawa S, Ohmagari N, Kato Y, Morita M. Case report: failure under azithromycin treatment in a case of bacteremia due to *Salmonella enterica* Paratyphi A. *BMC Infectious Diseases*. 2014. 14:404
- Sharma N, Hotta A, Yamamoto Y, Uda A, Fujita O, Mizoguchi T, Shindo J, Park CH, Kudo N, Hatai H, Oyamada T, Yamada A, Morikawa S, Tanabayashi K. Serosurveillance for *Francisella tularensis* among wild animals in Japan using a newly developed competitive enzyme-linked immunosorbent assay. *Vector Borne Zoonotic Dis*. 2014 Apr;14(4):234-239.
- Takayama-Ito M, Nakamichi K, Kinoshita H, Kakiuchi S, Kurane I, Saijo M, Lim CK. A sensitive in vitro assay for the detection of residual viable rabies virus in inactivated rabies vaccines. *Biologicals*. 2014 42(1):42-7.
- Tani H, Iha K, Shimojima M, Fukushi S, Taniguchi S, Yoshikawa T, Kawaoka Y, Nakasone N, Ninomiya H, Saijo M, Morikawa S. Analysis of Lujo virus cell entry using pseudotype vesicular stomatitis virus. *J Virol*. 88(13):7317-7330, 2014
- Uda A, Sekizuka T, Tanabayashi K, Fujita O, Kuroda M, Hotta A, Sugiura N, Sharma N, Morikawa S, Yamada A. Role of Pathogenicity Determinant Protein C (PdpC) in Determining the Virulence of the *Francisella tularensis* Subspecies *tularensis* SCHU. *PLoS One*. 18;9(2):e89075, 2014
- Saraya T, Tanabe K, Araki K, Yonetani S, Makino H, Watanabe T, Tsujimoto N, Takata S, Kurai D, Ishii H, Miyazaki Y, Takizawa H, Goto H. Breakthrough invasive *Candida glabrata* in patients on micafungin: a novel FKS gene conversion correlated with sequential elevation of MIC. *Journal of Clinical Microbiology*. 52(7):2709-2712, 2014.
- Kenri T, Sekizuka T, Yamamoto A, Iwaki M, Komiya T, Hatakeyama T, Nakajima H, Takahashi M, Kuroda M, Shibayama K. Genetic characterization and comparison of *Clostridium botulinum* isolates from botulism cases in Japan between 2006 and 2011. *Appl Environ Microbiol*. 80(22):6954-6964., 2014
- Koma T, Yoshimatsu K, Nagata N, Sato Y, Shimizu K, Yasuda SP, Amada T, Nishio S, Hasegawa H, Arikawa J. Neutrophil depletion suppresses pulmonary vascular hyperpermeability and occurrence of pulmonary edema caused by hantavirus infection in C.B-17 SCID mice. *J Virol*. 88:7178-7188, 2014
- Nagata N, Saijo M, Kataoka M, Ami Y, Suzaki Y, Sato Y, Iwata-Yoshikawa N, Ogata M, Kurane I, Morikawa S, Sata T, Hasegawa H. Pathogenesis of fulminant monkeypox with bacterial sepsis after experimental infection with West African monkeypox virus in a cynomolgus monkey. *Int J Clin Exp Pathol*. 7:4359-4370, 2014
- Sakai, K., Nagata, N., Ami, Y., Seki, F., Suzaki, Y., Iwata-Yoshikawa, N., Suzuki, T., Fukushi, S., Mizutani, T., Yoshikawa, T., Otsuki, N., Kurane, I., Komase, K., Yamaguchi, R., Hasegawa, H., Saijo, M., Takeda, M., Morikawa, S. (2013): Lethal canine distemper virus outbreak in cynomolgus monkeys in Japan in 2008. *J. Virol.*, 87(2), 1105-1114.
- Gaowa, Ohashi N, Aochi M, Wurito, Wu D, Yoshikawa Y, Kawamori F, Honda T, Fujita H, Takada N, Oikawa Y, Kawabata H, Ando S, Kishimoto T. Rickettsia-related pathogens in ticks, central to western Japan. *Emerging Infectious Diseases*. 19(2), 338-340, 2013.

- Mezaki K, Kobayashi T, Fujiya Y, Kutsuna S, Takeshita N, Kanagawa S, Ohnishi M, Izumiya H, Ohmagari N. Salmonella enterica serotype Paratyphi A carrying CTX-M-15 type extended-spectrum beta-lactamase isolated from a Japanese traveller returning from India, Japan, July 2013. *Eurosurveillance*. 2013, 18(46):pii=20632.
- Kewcharoenwong C, Rinchai D, Utispan K, Suwannasaen D, Bancroft G, Ato M*, Lertmemongkolchai G*. Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection. *Sci Rep*. 2013. 3:3363.
- Nakayama E, Saijo M. Animal models for Ebola and Marburg virus infections. *Front Microbiol*. 2013 Sep 5;4:267.
- Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. *J Virol*. 2013 Dec;87(23):12552-61.
- Taniguchi, S., Sayama, Y., Nagata, N., Ikegami, T., Miranda, M.E., Watanabe, S., Iizuka, I., Fukushi, S., Mizutani, T., Ishii, Y., Saijo, M., Akashi, H., Yoshikawa, Y., Kyuwa, S., Morikawa, S. (2012): Analysis of the humoral immune responses among cynomolgus macaque naturally infected with Reston virus during the 1996 outbreak in the Philippines. *BMC Vet. Res.*, 8, 189.
- Marzi, A., Yoshida, R., Miyamoto, H., Ishijima, M., Suzuki, Y., Higuchi, M., Matsuyama, Y., Igarashi, M., Nakayama, E., Kuroda, M., Saijo, M., Feldmann, F., Brining, D., Feldmann, H., Takada, A. (2012): Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. *PLoS One*, 7(4), e36192.
- Gaowa, Ohashi, N., Aochi, M., Wuritu, D., Wu, D., Yoshikawa, Y., Kawamori, F., Honda, T., Fujita, H., Takada, N., Oikawa, Y., Kawabata, H., Ando, S., Kishimoto, T. (2013): Rickettsia in ticks, Japan, *Emerg. Infect. Dis.*, 19(2), 338-340.
- Yuko UCHIDA, Nobuhiro TAKEMAE and Takehiko SAITO Application of reverse genetics for producing attenuated vaccine strains against highly pathogenic avian influenza viruses. *J Vet Med Sci*. 2014 Aug;76(8):1111-7.

Confidence-Building Measure "E"

Form E: Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No
(b) Exports of micro-organisms and toxins	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No
(c) Imports of micro-organisms and toxins	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No
(d) Biosafety and biosecurity	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No

Name of legislation, regulations, and other measures:

Foreign exchange and Foreign Trade Law (1948)

Law on Implementing the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction and the Other Conventions (1982)

Cabinet Order for the Enforcement of the Law on Implementing the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction (1995)

The Law Concerning the Prevention of Infections and Medical Care for Patients of Infections (1998)

Confidence-Building Measure "F"

Declaration of past activities in offensive and/or defensive biological research and development program

1. Date of entry into force of the Convention for the State Party

June 8, 1982

2. Past offensive biological research and development programmes:

None

3. Past defensive biological research and development programmes:

None

Confidence-Building Measure "G"

Form G : Declaration of vaccine production facilities

No.	Name of Facility	Location (postal address)	General Description of the Types of Diseases Covered
1	Denka Seiken Co., Ltd	2-1-1 Nihonbashi Muromachi, Chuo-ku, Tokyo, Japan	Influenza, Tetanus
2	Kitasato Daiichi Sankyo Vaccine Co.,Ltd	6-111 Arai, Kitamoto-shi, Saitama, Japan	Influenza, Rubella, Diphtheria, Tetanus, Pertussis, Measles, Mumps, Poliomyelitis
3	Takeda Pharmaceutical Co.,Ltd	4-1-1 Doshomachi, Chuo-ku, Osaka, Japan	Influenza, Diphtheria, Tetanus, Pertussis, Measles, Mumps, Rubella
4	The Research Foundation for Microbial Diseases of Osaka University (BIKEN)	3-1 Yamadaoka, Suita-shi, Osaka, Japan	Influenza, Diphtheria, Tetanus, Varicella, Japanese Encephalitis, Pertussis, Measles, Rubella, Poliomyelitis
5	The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN)	1-6-1 Okubo, Kita-ku, Kumamoto-shi, Kumamoto, Japan	Influenza, Rabies, Diphtheria, Tetanus, Japanese Encephalitis, Pertussis, Mumps, Hepatitis A, Hepatitis B, Poliomyelitis
6	Japan BCG Laboratory	4-2-6 Kohinata, Bunkyo-ku, Tokyo, Japan	Tuberculosis
7	Japan Poliomyelitis Research Institute	5-34-4 Kumegawa-cho, Higashimurayama-shi, Tokyo, Japan	Poliomyelitis